FDA, Clinical Trials, AstraZeneca Corey Hubbard FDA, Clinical Trials, AstraZeneca Corey Hubbard

AIM ImmunoTech & AstraZeneca's Ampligen-Imfinzi Combo Shows Promising Data in Pancreatic Cancer Trial (DURIPANC)

The landscape of medical innovation is constantly evolving, with dedicated researchers and pharmaceutical companies striving to tackle some of the most challenging diseases known to humankind. One such formidable adversary is pancreatic cancer, a condition often dubbed a "silent killer" due to its aggressive nature and typically late diagnosis.

Read More
Clinical Trials, FDA, Therapeutics Corey Hubbard Clinical Trials, FDA, Therapeutics Corey Hubbard

Revolutionizing Alzheimer's Treatment: Hope on the Horizon with New Drug Discoveries

Alzheimer's disease is a progressive and devastating condition that slowly steals memories, thinking skills, and eventually, the ability to carry out even the simplest tasks. For individuals and their families, the journey with Alzheimer's is often heartbreaking, marked by a relentless decline in cognitive function

Read More
Therapeutics, Clinical Trials, FDA Corey Hubbard Therapeutics, Clinical Trials, FDA Corey Hubbard

Hope on the Horizon: Unpacking Roche's Promising Alzheimer's Therapy and Its Potential Impact

Alzheimer's disease represents a profound global health challenge, a progressive neurological disorder that gradually erodes memory, thinking skills, and, eventually, the ability to carry out even the simplest tasks. For individuals and their families, the journey with Alzheimer's

Read More
Clinical Trials, FDA, Therapeutics Corey Hubbard Clinical Trials, FDA, Therapeutics Corey Hubbard

Breathing Easier? BiomX's Revolutionary Phage Therapy for Cystic Fibrosis Enters Advanced Trials

Cystic Fibrosis (CF) is a complex genetic disease that severely impacts multiple organs, particularly the lungs. For many CF patients, the persistent presence of stubborn bacterial infections in the lungs poses a life-threatening challenge. Among these, chronic pulmonary infections caused by Pseudomonas aeruginosa

Read More
AntiBody, Clinical Trials, FDA Corey Hubbard AntiBody, Clinical Trials, FDA Corey Hubbard

Revolutionizing Medicine: How Chai-2's AI is Designing Life-Saving Antibodies in Weeks, Not Years

Imagine a world where the discovery of new medicines, particularly those designed to fight diseases with incredible precision, could happen at lightning speed. For decades, this process has been slow, incredibly expensive, and often riddled with failures. But a groundbreaking innovation named Chai-2 is changing that reality, ushering in an unprecedented era of rapid and precise molecular engineering

Read More
Clinical Trials, Therapeutics, FDA Corey Hubbard Clinical Trials, Therapeutics, FDA Corey Hubbard

A New Era in HIV Prevention: Monthly Pills and Long-Acting Injections Transform PrEP

The global fight against Human Immunodeficiency Virus (HIV) has seen incredible progress, yet the need for innovative prevention methods remains urgent. In 2023 alone, 1.3 million people acquired HIV, underscoring the continuous demand for effective strategies. Among the most powerful tools in this fight is pre-exposure prophylaxis, or PrEP

Read More
Clinical Trials, Therapeutics, FDA Corey Hubbard Clinical Trials, Therapeutics, FDA Corey Hubbard

Hope on the Horizon: A Breakthrough Approach to Taming Severe Cholesterol with Zodasiran

In the vast and ever-evolving landscape of medical innovation, breakthroughs often emerge that promise to reshape the future of patient care. These advancements are typically the result of dedicated research and rigorous clinical trials, shining a beacon of hope for individuals grappling with challenging health conditions.

Read More
Clinical Trials, Therapeutics, FDA Corey Hubbard Clinical Trials, Therapeutics, FDA Corey Hubbard

PTSD Breakthrough: FDA Designates TSND-201 for Rapid Relief

The recent announcement by Transcend Therapeutics regarding the US Food and Drug Administration (FDA) granting breakthrough therapy designation to their drug, TSND-201, for the treatment of Post-Traumatic Stress Disorder (PTSD) marks a significant moment for the millions of Americans living with this debilitating condition. This designation is a beacon of hope, promising to accelerate the development and review

Read More
Healthcare, Full Disclosure, Access Corey Hubbard Healthcare, Full Disclosure, Access Corey Hubbard

Triumphant Return: Judge Orders FDA to Restore Vital Clinical Trial Diversity Webpages, Empowering Health Equity!

Embrace a momentous win for health equity! A US District Judge has courageously ordered the FDA and HHS to fully reinstate crucial healthcare resources, including vital clinical trial diversity webpages. This landmark ruling reverses the unlawful removal of content, ensuring that healthcare providers, policymakers, and local governments can once again rely on essential data and information to drive progress in health outcomes. This decision powerfully upholds federal laws like the Administrative Procedure Act (APA), reinforcing proper governance and the government's obligation to its citizens. It's a powerful affirmation of the importance of diversity in clinical trials and a bright, hopeful step forward for informed, inclusive healthcare initiatives across the nation!

Read More
Wellness, Healthcare, Innovation Corey Hubbard Wellness, Healthcare, Innovation Corey Hubbard

Bridging the Gap: Understanding Digital Mental Health Tools in Everyday Healthcare

Mental health is a crucial part of our overall well-being, yet for many people, especially those in underserved communities, getting the right mental health care can be incredibly difficult. They might face numerous obstacles, like a lack of local specialists, high costs, or the stigma often associated with seeking mental health support.

Read More
Medical, Research, Therapeutics Corey Hubbard Medical, Research, Therapeutics Corey Hubbard

Revolutionizing Research: The CardioCare Research Suite's Impact on Clinical Trials

The landscape of medical research, particularly in the realm of clinical trials, is incredibly complex, with numerous challenges often impeding the swift progress of potentially life-saving treatments. One of the most significant hurdles faced by research teams globally is the identification and recruitment of suitable patients

Read More
Therapeutics, Clinical Trials, FDA Corey Hubbard Therapeutics, Clinical Trials, FDA Corey Hubbard

Unpacking PulseSight's Pioneering Trial for Dry AMD and Geographic Atrophy

Our eyes are windows to the world, allowing us to experience the vibrant tapestry of life. However, certain conditions can threaten this precious sense, leading to significant vision loss. Among the most common causes of vision impairment in older adults are dry Age-related Macular Degeneration (AMD) and its advanced form, Geographic Atrophy (GA)

Read More